NeuroOne Medical TechnologiesNMTC
NMTC
About: NeuroOne Medical Technologies Corp operates as a medical technology company. It is focused on the development and commercialization of thin-film electrode technology for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording, brain stimulation, and ablation solutions for patients suffering from brain-related disorders. The company business is in one operating segment, which is the business of development and commercialization of products related to comprehensive neuromodulation cEEG and sEEG recording, monitoring, ablation, and brain stimulation solutions.
Employees: 17
0
Funds holding %
of 7,425 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
2.62% less ownership
Funds ownership: 7.87% [Q3] → 5.25% (-2.62%) [Q4]
5% less funds holding
Funds holding: 21 [Q3] → 20 (-1) [Q4]
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
44% less capital invested
Capital invested by funds: $2.4M [Q3] → $1.34M (-$1.06M) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for NMTC.
Financial journalist opinion
Based on 6 articles about NMTC published over the past 30 days
Neutral
GlobeNewsWire
1 week ago
NeuroOne® Completes FDA Submission for the OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain
Multi-Contact Probe Provides Alternative to Pharmaceutical and Invasive Surgical Treatments Submission Completed Earlier Than Anticipated EDEN PRAIRIE, Minn., April 23, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, has filed its 510(k) submission to the FDA for trigeminal nerve ablation earlier than previous guidance.
Neutral
GlobeNewsWire
2 weeks ago
NeuroOne® Issues Letter to Shareholders
Company Now Fully Funded Through at least Fiscal 2026; Company Confirms No Material Impact from Global Tariffs EDEN PRAIRIE, Minn., April 16, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, has issued a letter to shareholders from CEO, Dave Rosa.
Neutral
GlobeNewsWire
2 weeks ago
NeuroOne® OneRF® Technology Success Story Featured on Fox News
Pediatric Patient Treated with OneRF® Ablation System Goes From Up to 10 Nightly Seizures to Zero EDEN PRAIRIE, Minn., April 14, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today that its proprietary OneRF® Ablation System was recently featured in a national Fox News article highlighting the successful treatment of a pediatric epilepsy patient.
Negative
Benzinga
3 weeks ago
Nasdaq Dips 5%; NeuroOne Medical Technologies Shares Plummet
U.S. stocks traded lower midway through trading, with the Dow Jones index dipping more than 1,100 points on Friday. Beijing unveiled a retaliatory 34% tariff on U.S. goods—mirroring the rate announced by President Donald Trump on Wednesday—deepening fears of a full-blown trade war.
Neutral
GlobeNewsWire
3 weeks ago
NeuroOne Medical Technologies Corporation Announces Pricing of $8.0 Million Public Offering of Common Stock
EDEN PRAIRIE, Minn., April 04, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today the pricing of an underwritten registered public offering of 16,000,000 shares of its common stock at a price of $0.50 per share.
Neutral
GlobeNewsWire
3 weeks ago
NeuroOne Medical Technologies Corporation Announces Proposed Public Offering of Common Stock
EDEN PRAIRIE, Minn., April 03, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today that it has commenced a proposed underwritten registered public offering of shares of its common stock.
Neutral
GlobeNewsWire
1 month ago
NeuroOne® CEO Dave Rosa Discusses Epilepsy Treatment Innovations on Today's Marketplace - Update
EDEN PRAIRIE, Minn., March 18, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today that CEO Dave Rosa was featured on Today's Marketplace (TMP) alongside Dr. Jessica Clark, DNP, RN, Dean of the College of Nursing at Creighton University. The discussion explored the latest advancements in epilepsy treatment and NeuroOne's breakthrough OneRF® Ablation System.
Neutral
GlobeNewsWire
1 month ago
NeuroOne® CEO Dave Rosa Discusses Epilepsy Treatment Innovations on Today's Marketplace
EDEN PRAIRIE, Minn., March 18, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today that CEO Dave Rosa was featured on Today's Marketplace (TMP) alongside Dr. Jessica Clark, DNP, RN, Dean of the College of Nursing at Creighton University.
Neutral
GlobeNewsWire
1 month ago
NeuroOne CEO Joins Today's Marketplace To Discuss The Latest Treatments for Epilepsy
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Today's Marketplace (TMP) is proud to announce a featured interview with NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) CEO Dave Rosa and Jessica Clark, DNP, RN, Dean of the College of Nursing at Creighton University. The pair joined Today's Marketplace host Elizabeth Hart to discuss the latest treatments for epilepsy The full interview can be viewed online here.
Neutral
GlobeNewsWire
1 month ago
NeuroOne® Accelerates Timeline of 510(k) Submission to FDA for the OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain
Submission for New Intended Use That Leverages Company's Patented OneRF® Technology Platform Expected in May 2025 EDEN PRAIRIE, Minn., March 11, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, has accelerated the anticipated timeline of its 510(k) submission to the FDA for trigeminal nerve ablation to May 2025, which leverages the Company's patented OneRF® Technology Platform.
Charts implemented using Lightweight Charts™